Apellis Pharmaceuticals Inc
General ticker "APLS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.2B
Apellis Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -31.1%.
Estimated limits based on current volatility of 2.5%: low 32.86$, high 34.54$
Factors to consider:
- Company does not operate outside North America (retrieved using AI)
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [31.68$, 71.47$]
- 2024-12-30 to 2025-12-30 estimated range: [25.51$, 59.36$]
Financial Metrics affecting the APLS estimates:
- Negative: Non-GAAP EPS, $ of -4.48 <= 0.10
- Negative: Operating profit margin, % of -56.60 <= 1.03
- Negative: Operating cash flow per share per price, % of -8.00 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term APLS quotes
Long-term APLS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $66.56MM | $75.42MM | $396.59MM |
| Operating Expenses | $602.84MM | $670.03MM | $913.71MM |
| Operating Income | $-536.28MM | $-594.61MM | $-517.12MM |
| Non-Operating Income | $-209.72MM | $-56.89MM | $-9.38MM |
| Interest Expense | $13.24MM | $32.63MM | $29.58MM |
| R&D Expense | $420.87MM | $387.24MM | $354.39MM |
| Income(Loss) | $-746.00MM | $-651.50MM | $-526.50MM |
| Taxes | $0.35MM | $0.67MM | $2.13MM |
| Profit(Loss) | $-746.35MM | $-652.17MM | $-528.63MM |
| Stockholders Equity | $198.66MM | $169.87MM | $194.52MM |
| Inventory | $16.29MM | $85.71MM | $146.36MM |
| Assets | $881.76MM | $760.22MM | $788.73MM |
| Operating Cash Flow | $-563.13MM | $-513.75MM | $-594.74MM |
| Capital expenditure | $1.10MM | $1.52MM | $0.77MM |
| Investing Cash Flow | $247.62MM | $59.89MM | $-0.67MM |
| Financing Cash Flow | $392.24MM | $365.66MM | $394.50MM |
| Earnings Per Share* | $-8.84 | $-6.15 | $-4.45 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.